Patent ID: 8716278
Filing Date: 2014-05-06
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition comprising: a first drug substance selected from the group consisting of: amorphous racemic-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic racemic-methylphenidate stearylamine pamoate characterized by at least one method selected from the group consisting of: amorphous d-methylphenidate pamoate characterized by at least one method selected from the group consisting of: amorphous d-methylphenidate xinafoate characterized by at least one method selected from the group consisting of: polymorphic dextro-amphetamine xinafoate characterized by at least one method selected from the group consisting of: polymorphic d-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic racemic-methylphenidate pamoate characterized by at least one method selected from the group consisting of: polymorphic racemic-methylphenidate xinafoate characterized by at least one method selected from the group consisting of: amorphous dextro-amphetamine pamoate characterized by at least one method selected from the group consisting of: polymorphic dextro-amphetamine pamoate characterized by at least one method selected from the group consisting of: amorphous d-methylphenidate mono-triethylammonium pamoate characterized by at least one method selected from the group consisting of: amorphous imipramine mono-triethylammonium pamoate characterized by at least one method selected from the group consisting of: polymorphic imipramine stearylamine pamoate characterized by at least one method selected from the group consisting of: amorphous imipramine, CH amorphous hydrocodone stearylamine pamoate characterized by at least one method selected from the group consisting of: amorphous hydrocodone, CH polymorphic imipramine pamoate (1:1) characterized by at least one method selected from the group consisting of: amorphous imipramine pamoate (1:1) characterized by at least one method selected from the group consisting of: with a first percent dissolution at a pH of 1 at 60 minutes at ambient temperature; and a second drug substance consisting essentially of a salt of a second amine containing pharmaceutically active compound with a second percent dissolution at a pH of 1 at 60 minutes at ambient temperature.